The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on anemia management (…
Chronic kidney disease (CKD) affects approximately 26 million people in the United States. While there are multiple prescription therapies that are available for treating the associated symptoms,…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
Payer and Physician Receptivity to Novel Treatments—Which Emerging Drugs Excite Them? Hyperphosphatemia, or treatment of elevated serum phosphorous levels, typically found as a complication of…
Payer and Physician Receptivity to Novel Treatments—Which Emerging Drugs Excite Them? Hyperphosphatemia, or treatment of elevated serum phosphorous levels, typically found as a complication of…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Myelodysplastic syndromes (MDS) consists of a group of disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis and deteriorating…